Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Novel approaches to the treatment of depression by modulating the hypothalamic – pituitary – adrenal axis

Novel approaches to the treatment of depression by modulating the hypothalamic – pituitary –... Many patients with major depression show evidence of over‐activation of the hypothalamic – pituitary – adrenal axis (HPA), as evidenced by hypercortisolism and adrenal hyperplasia. Such over‐activity is associated with increased corticotropin releasing factor (CRF) reactivity in the CSF and blunted release of ACTH in response to CRF infusion. Recent evidence suggests a switch from CRF to AVP regulation of the axis during depression, with depressed patients showing enhanced response to ddAVP infusion. The HPA provides multiple potential sites for antidepressant development. The use of glucocorticoid antagonists, cortisol synthesis inhibitors, CRF and AVP antagonists have been suggested. Copyright © 2001 John Wiley & Sons, Ltd. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Human Psychopharmacology: Clinical and Experimental Wiley

Novel approaches to the treatment of depression by modulating the hypothalamic – pituitary – adrenal axis

Loading next page...
 
/lp/wiley/novel-approaches-to-the-treatment-of-depression-by-modulating-the-TDRqjQ03yy

References (29)

Publisher
Wiley
Copyright
Copyright © 2001 John Wiley & Sons, Ltd.
ISSN
0885-6222
eISSN
1099-1077
DOI
10.1002/hup.188
Publisher site
See Article on Publisher Site

Abstract

Many patients with major depression show evidence of over‐activation of the hypothalamic – pituitary – adrenal axis (HPA), as evidenced by hypercortisolism and adrenal hyperplasia. Such over‐activity is associated with increased corticotropin releasing factor (CRF) reactivity in the CSF and blunted release of ACTH in response to CRF infusion. Recent evidence suggests a switch from CRF to AVP regulation of the axis during depression, with depressed patients showing enhanced response to ddAVP infusion. The HPA provides multiple potential sites for antidepressant development. The use of glucocorticoid antagonists, cortisol synthesis inhibitors, CRF and AVP antagonists have been suggested. Copyright © 2001 John Wiley & Sons, Ltd.

Journal

Human Psychopharmacology: Clinical and ExperimentalWiley

Published: Jan 1, 2001

There are no references for this article.